For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:<\/p>\n\n\n\n
This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:<\/p>\n\n\n\n
For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n
The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026<\/strong>, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine<\/strong> (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times<\/strong> (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.<\/p>\n\n\n\n India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.<\/p>\n\n\n\n\n For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:<\/p>\n\n\n\n This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:<\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n Breast cancer is the most common cancer among Indian women<\/strong>, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.<\/p>\n\n\n\n Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.<\/p>\n\n\n\n\n The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026<\/strong>, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine<\/strong> (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times<\/strong> (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.<\/p>\n\n\n\n India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.<\/p>\n\n\n\n\n For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:<\/p>\n\n\n\n This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:<\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n The CDSCO’s approval covers AstraZeneca Pharma India’s application to import and distribute<\/strong> Enhertu in India. According to reporting by Medical Dialogues<\/strong> (July 28, 2026) and NDTV Profit<\/strong> (August 8, 2026), the approval was specifically for the neoadjuvant treatment of HER2-positive breast cancer<\/strong> in the Stage II\/III setting \u2014 meaning the drug can be used before surgery to shrink tumours and improve surgical outcomes.<\/p>\n\n\n\n The Economic Times<\/strong> (June 11, 2026) had earlier reported that Enhertu received regulatory approval in India for first-line HER2-positive breast cancer, indicating that the CDSCO approval process for this drug has been progressing through multiple indication stages throughout 2026.<\/p>\n\n\n\n\n Breast cancer is the most common cancer among Indian women<\/strong>, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.<\/p>\n\n\n\n Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.<\/p>\n\n\n\n\n The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026<\/strong>, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine<\/strong> (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times<\/strong> (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.<\/p>\n\n\n\n India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.<\/p>\n\n\n\n\n For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:<\/p>\n\n\n\n This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:<\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n\n\n\n Enhertu is a targeted antibody-drug conjugate (ADC)<\/strong> that combines a monoclonal antibody (trastuzumab) with a cytotoxic chemotherapy agent (deruxtecan). It is designed to target the HER2 protein, which is overexpressed in approximately 15-20% of breast cancers<\/strong>, according to established oncology literature. The drug delivers chemotherapy directly into HER2-positive cancer cells while sparing healthy tissue, representing a precision-medicine approach to breast cancer treatment.<\/p>\n\n\n\n Enhertu has been approved in multiple countries including the United States (FDA, 2019) and the European Union (EMA) for various HER2-positive breast cancer indications. The CDSCO approval brings this treatment option to Indian patients who previously had limited access to this class of therapy.<\/p>\n\n\n\n\n The CDSCO’s approval covers AstraZeneca Pharma India’s application to import and distribute<\/strong> Enhertu in India. According to reporting by Medical Dialogues<\/strong> (July 28, 2026) and NDTV Profit<\/strong> (August 8, 2026), the approval was specifically for the neoadjuvant treatment of HER2-positive breast cancer<\/strong> in the Stage II\/III setting \u2014 meaning the drug can be used before surgery to shrink tumours and improve surgical outcomes.<\/p>\n\n\n\n The Economic Times<\/strong> (June 11, 2026) had earlier reported that Enhertu received regulatory approval in India for first-line HER2-positive breast cancer, indicating that the CDSCO approval process for this drug has been progressing through multiple indication stages throughout 2026.<\/p>\n\n\n\n\n Breast cancer is the most common cancer among Indian women<\/strong>, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.<\/p>\n\n\n\n Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.<\/p>\n\n\n\n\n The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026<\/strong>, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine<\/strong> (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times<\/strong> (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.<\/p>\n\n\n\n India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.<\/p>\n\n\n\n\n For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:<\/p>\n\n\n\n This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:<\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n\n The Central Drugs Standard Control Organisation (CDSCO) has approved AstraZeneca Pharma India’s application to import and distribute Enhertu (trastuzumab deruxtecan)<\/strong> for the treatment of HER2-positive breast cancer, marking a significant addition to India’s oncology drug portfolio. The approval was reported by multiple industry publications on September 13, 2026.<\/p>\n\n\n\n\n Enhertu is a targeted antibody-drug conjugate (ADC)<\/strong> that combines a monoclonal antibody (trastuzumab) with a cytotoxic chemotherapy agent (deruxtecan). It is designed to target the HER2 protein, which is overexpressed in approximately 15-20% of breast cancers<\/strong>, according to established oncology literature. The drug delivers chemotherapy directly into HER2-positive cancer cells while sparing healthy tissue, representing a precision-medicine approach to breast cancer treatment.<\/p>\n\n\n\n Enhertu has been approved in multiple countries including the United States (FDA, 2019) and the European Union (EMA) for various HER2-positive breast cancer indications. The CDSCO approval brings this treatment option to Indian patients who previously had limited access to this class of therapy.<\/p>\n\n\n\n\n The CDSCO’s approval covers AstraZeneca Pharma India’s application to import and distribute<\/strong> Enhertu in India. According to reporting by Medical Dialogues<\/strong> (July 28, 2026) and NDTV Profit<\/strong> (August 8, 2026), the approval was specifically for the neoadjuvant treatment of HER2-positive breast cancer<\/strong> in the Stage II\/III setting \u2014 meaning the drug can be used before surgery to shrink tumours and improve surgical outcomes.<\/p>\n\n\n\n The Economic Times<\/strong> (June 11, 2026) had earlier reported that Enhertu received regulatory approval in India for first-line HER2-positive breast cancer, indicating that the CDSCO approval process for this drug has been progressing through multiple indication stages throughout 2026.<\/p>\n\n\n\n\n Breast cancer is the most common cancer among Indian women<\/strong>, accounting for a significant proportion of new cancer cases each year. HER2-positive breast cancer, while a subset of all breast cancers, is an aggressive form that requires targeted therapy for optimal outcomes.<\/p>\n\n\n\n Prior to this approval, Indian patients with HER2-positive breast cancer had access to trastuzumab (Herceptin) and pertuzumab-based regimens. Enhertu represents a newer generation of HER2-targeted therapy with demonstrated efficacy in patients who have progressed on earlier treatments, as shown in international clinical trials.<\/p>\n\n\n\n\n The Enhertu approval comes amid a broader pattern of CDSCO activity on cancer drugs throughout 2026. In July 2026<\/strong>, the CDSCO also cleared expanded use of Intas Pharma’s Trastuzumab Emtansine<\/strong> (another HER2-targeted ADC) for breast cancer, as reported by The Economic Times<\/strong> (July 22, 2026). These approvals reflect the regulator’s increasing focus on expanding access to modern oncology therapies in the Indian market.<\/p>\n\n\n\n India’s pharmaceutical industry is the world’s largest provider of generic medicines by volume, but access to novel targeted therapies and antibody-drug conjugates has historically lagged behind regulated markets. Each new oncology drug approval by the CDSCO represents a stepwise expansion of treatment options available to Indian oncologists and patients.<\/p>\n\n\n\n\n For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include:<\/p>\n\n\n\n This article is based on coverage from the following sources reporting on the CDSCO approval of AstraZeneca’s Enhertu for HER2-positive breast cancer:<\/p>\n\n\n\n For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n","protected":false},"excerpt":{"rendered":" What This Means for Patients and Providers For oncologists and patients in India, the Enhertu approval provides an additional tool in the HER2-positive breast cancer treatment arsenal. Key practical considerations include: Treatment sequencing: Enhertu may be used in patients who have already received prior HER2-targeted therapies, offering a later-line option with a different mechanism of […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[42,48,49],"class_list":["post-3699","post","type-post","status-publish","format-standard","hentry","category-news","tag-cdsco","tag-generic-medicines","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3699"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3699\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What This Means for Patients and Providers<\/h2>\n\n\n\n
\n
Sources<\/h2>\n\n\n\n
\n
\n\n\n\nHER2-Positive Breast Cancer in India<\/h2>\n\n\n\n
India’s Broader Oncology Drug Landscape<\/h2>\n\n\n\n
What This Means for Patients and Providers<\/h2>\n\n\n\n
\n
Sources<\/h2>\n\n\n\n
\n
\n\n\n\nThe CDSCO Approval: Scope and Significance<\/h2>\n\n\n\n
HER2-Positive Breast Cancer in India<\/h2>\n\n\n\n
India’s Broader Oncology Drug Landscape<\/h2>\n\n\n\n
What This Means for Patients and Providers<\/h2>\n\n\n\n
\n
Sources<\/h2>\n\n\n\n
\n
\n\n\n\nWhat Is Enhertu and How It Works<\/h2>\n\n\n\n
The CDSCO Approval: Scope and Significance<\/h2>\n\n\n\n
HER2-Positive Breast Cancer in India<\/h2>\n\n\n\n
India’s Broader Oncology Drug Landscape<\/h2>\n\n\n\n
What This Means for Patients and Providers<\/h2>\n\n\n\n
\n
Sources<\/h2>\n\n\n\n
\n
\n\n\n\nWhat Is Enhertu and How It Works<\/h2>\n\n\n\n
The CDSCO Approval: Scope and Significance<\/h2>\n\n\n\n
HER2-Positive Breast Cancer in India<\/h2>\n\n\n\n
India’s Broader Oncology Drug Landscape<\/h2>\n\n\n\n
What This Means for Patients and Providers<\/h2>\n\n\n\n
\n
Sources<\/h2>\n\n\n\n
\n
\n\n\n\n